Long-Term Biosimilar Sustainability Is At A Tipping Point, Report Says
New Policy Levers Are Needed For A Balanced And Sustainable Biosimilar Market
The current cost-saving benefits of biosimilars may soon be overturned by an unsustainable system that favors originator drugs, lower profits, and increased discounts, according to a new report.
